Human iPSC-Derived Ventricular Cardiomyocytes (1 million cells)
The induced pluripotent stem cells (iPSCs) used to generate Human iPSC-Derived Ventricular Cardiomyocytes (male, ax2520) have been well characterized and used widely within the research community. For iPSC characterization information please see ‘Baghbaderani BA, Tian X, Neo BH, et al. cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications. Stem Cell Reports (2015)’.
CD34+ cord blood cells were reprogrammed using episomal vectors under current good manufacturing practice (cGMP) conditions to produce a master bank of iPSCs. A non-GMP, research grade working bank of iPSCs were created from the master stock of cGMP-grade iPSCs for research studies (Baghbaderani et al., 2015). Axol has differentiated these matching research grade iPSCs into ventricular cardiomyocytes, as such these Human iPSC-Derived Ventricular Cardiomyocytes can be used for pre-clinical applications.